stockrow
Saturday 7 November 2026
Export BSEM’s income statement to Excel — free account
BioStem Technologies, Inc.
BSEM Healthcare Biotechnology
- Revenue
- −28.0%
- EPS
- −86,766.7%
Quarter to June 2026, against a year earlier
1.13
0.09
+8.65%
Follow BSEM
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
3.72 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.40 | 0.61 | 1.80 | 1.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
0.00 | 1.63 | 1.74 | 2.07 | |
Price to Tangible BV |
0.00 | 1.65 | 1.75 | 12.11 | |
EV/Sales |
0.40 | 0.33 | 1.02 | 1.45 | |
EV/EBITDA |
0.42 | 0.37 | 1.43 | 2.75 | |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | |
Quick Ratio |
— | 3.66 | — | 0.64 | |
Current Ratio |
— | 4.12 | — | 0.98 | |
Net Debt/EBITDA |
0.00 | (2.93) | 0.00 | 0.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | — | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 9.29% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 149.62% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.47 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.00 | 0.53 | 0.49 | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
26.88% | (9.17%) | (25.41%) | (46.81%) | |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | |
Revenue per Share |
0.63 | 0.60 | 0.36 | 0.46 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 1.76 | 0.00 | 0.40 | |
Shareholders Equity per Share |
0.00 | 2.34 | 0.00 | 1.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 2.34 | 0.00 | 1.59 | |
EV/EBIT |
0.42 | 0.37 | 1.43 | 2.75 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.42 | 0.68 | 2.53 | 3.13 | |
| Other line items | |||||
Working Capital |
— | 33.62 | — | (0.42) | |
Net Current Asset Value |
— | 33.51 | — | (0.42) | |
Average Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026